Overview

Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label extension trial conducted at the same European sites that participated in trial SP 709 (NCT00243217). The trial is designed to collect long-term safety and tolerability, efficacy correlates, and quality of life data in subjects with idiopathic Restless Leg Syndrome (RLS). The duration of treatment is approximately 5 years. Subject will be up-titrated to their optimal dose (administration of 1 patch per day, 5 different doses and patch sizes).
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
N 0437
Rotigotine